Testing a new drug for sickle cell disease in healthy people and patients
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This early-phase study tests a new drug (BMS-986470) for people with sickle cell disease who have frequent pain crises. The goal is to see if it can safely reduce crises. It includes a small group of healthy volunteers as well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of sickle cell disease with a specific type (HbSS, HbSβ0-thal, or HbSβ+-thal)
- You need to have had between 2 and 15 severe pain crises in the last year (depending on the part of the study)
- You cannot be on regular red blood cell or platelet transfusions, and you must not have had a transfusion recently
- You must be able to carry out daily activities with little or no help (ECOG score of 0 or 1)
- If you're in Part 1, you cannot have had acute chest syndrome or more than 6 severe crisis hospital stays in the last year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug (BMS-986521) in healthy volunteers to see how safe it is and how the body processes it. It helps researchers decide if the drug can be tested in future studies.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This study tests an investigational oral pill called etavopivat that may help reduce pain crises in people with sickle cell disease. You may qualify if you have frequent pain crises and are not on regular blood transfusions.
This trial tests a new medicine called ITU512 in two groups: healthy volunteers and people with sickle cell disease. In the second part, researchers want to see if ITU512 can help manage sickle cell disease.
This study tests a medication called fostamatinib to see if it is safe and tolerable for people with sickle cell disease. It may offer a new treatment option for managing the condition.
This early-phase study tests panobinostat, a medicine aimed at reducing sickle-cell problems, in adults with severe disease. It’s mainly looking at safety and whether it can improve blood-related issues that drive pain and complications.
Hear when a new Anemia, Sickle Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.